BML Capital Management, an activist investor that owns 9.9% of Elevation’s shares, is urging the company to wind down ...

A pill developed by GSK was found to be safe and effective in treating gonorrhea in a late-stage clinical trial. Novartis ...

After San Francisco biotech company Third Harmonic Bio slashed its staff by half in February, it's now taking a more drastic ...

I'm on the older side of this whole journey, which is another interesting dimension that I call the third act. Music is that third act." ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

San Francisco, USA-based inflammatory disease biotech Third Harmonic Bio (Nasdaq: THRD) saw its shares rocket almost 40% to $5.09 as the company revealed an orderly exit plan.

Three recent moves show how stalled drug developers are funneling cash back to investors, either as they close up shop or ...

The Atlas-backed company plans to liquidate its assets, including an experimental drug for chronic spontaneous urticaria it ...

Third Harmonic Bio ( NASDAQ: THRD) will be liquidating the company and selling its remaining assets, the company said on ...

Third Harmonic Bio Inc (NASDAQ:THRD) shares are soaring on Monday after the company announced a plan of liquidation and dissolution.

Dell Technologies Inc. DELL climbed 5.8% to $86.73 in pre-market trading after the Trump administration excluded a range of ...

Third Harmonic Bio has abandoned plans to take its chronic spontaneous urticaria (CSU) drug into phase 2, instead preparing ...